# LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

> **NCT04219319** · PHASE1 · TERMINATED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 4 (actual)

## Conditions studied

- CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

## Interventions

- **DRUG:** Efficacy of LCAR-T2C CAR-T cells

## Key facts

- **NCT ID:** NCT04219319
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Both the sponsors and collaborator are considering terminating the study
- **Last updated:** 2022-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04219319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04219319, "LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04219319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*